Login / Signup

Time for reform in transplant program-specific reporting: AST/ASTS transplant metrics taskforce.

Anil ChandrakerKenneth A AndreoniRobert S GastonJohn GillJayme E LockeAmit K MathurDouglas J NormanRachel E PatzerAbbas A RanaLloyd E RatnerJesse D ScholdTimothy L Pruettnull null
Published in: American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons (2019)
In accordance with the National Organ Transplant Act and Department of Health and Human Services' Final Rule, the Scientific Registry of Transplant Recipients (SRTR) publicly releases biannual program-specific reports that include analyses of transplant centers' risk-adjusted waitlist mortality, organ acceptance ratios, transplant rates, and graft and patient survival. Since the inception of these center metrics, 1-year posttransplant graft and patient survival have improved, and center variation has decreased, casting uncertainty on their clinical relevance. The SRTR has recently modified center evaluations by ranking centers into 5 tiers rather than 3 tiers in an attempt to discriminate between programs performing within a tight range, further exacerbating this uncertainty. The American Society of Transplantation/American Society of Transplant Surgeons convened an expert taskforce to examine both the utility and unintended consequences of transplant center metrics. Estimates of center variation in outcomes in adjacent tiers are imprecise and fleeting, but can result in consequential changes in clinician and center behavior. The taskforce has concerns that current metrics, based principally on 1-year graft and patient survival, provide minimal if any benefit in informing patient choice and access to transplantation, with the untoward effect of decreased utilization of organs and restriction of research and innovation.
Keyphrases
  • case report
  • quality improvement
  • healthcare
  • public health
  • primary care
  • stem cells
  • endothelial cells
  • skeletal muscle
  • mesenchymal stem cells
  • insulin resistance
  • cardiovascular disease
  • health insurance
  • drug induced